trial

Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia

NCTId NCT00463372
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 40
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
40
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-10
Primary completion
—
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-02545920

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

1 total
George, South Africa

Facts & assertions

3 sourced
Enrollment
40
Phase
PHASE1
Status
COMPLETED
relationships
The graph out of here
drug
PF-02545920
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizo-affective Disorder
indication
Schizophrenia
indication